Nov 6 (Reuters) - Qiagen ( QGEN ) reported a rise in

third-quarter revenue on Wednesday, owing to strong sales of its

diagnostic devices.

The company's third-quarter net sales rose 6% to $502

million at constant exchanges rates (CER), which was above its

forecast of at least $495 million CER.

Diagnostics firm Qiagen ( QGEN ) said the sales growth was driven in

part by its diagnostic testing devices QuantiFERON and

QIAstat-Dx.

The company also said it is reaffirming its 2024 sales

forecast of at least $1.99 billion CER, "based on the solid core

business performance in the first nine months of the year."

It also raised its annual adjusted profit forecast to at

least $2.19 CER from $2.10 CER.

"We are implementing initiatives to simplify Qiagen ( QGEN ) and

increase efficiency, and these initiatives are putting us on

track to increase our adjusted operating income margin above 31%

by the end of 2028, reaffirming our commitment to solid

profitable growth," CFO Roland Sackers said in a statement.

In June, Qiagen ( QGEN ) issued a goal for adjusted operating income

margin of at least 31% in 2028, up from 26.9% in 2023, by

winding down unprofitable products and simplifying the

organization.

On an adjusted basis, Qiagen ( QGEN ) reported third-quarter profit

of 58 cents per share at CER.